ON TARGET LABS
PharmaON TARGET LABS is a pharmaceutical company focused on Oncology. Key products include CYTALUX.
FDA Novel Drug Designations
(2021)See 1 novel approval →
ON TARGET LABS at a Glance
- Strong track record with 92% execution quality across 5 trials
- Fast trial execution (19 months median completion)
Upcoming FDA Decisions
Full Calendar →ON TARGET LABS's Key Drugs
ON TARGET LABS's core commercial portfolio centers on CYTALUX, spanning Oncology — its most strategically important drugs approved in the last 15 years.
ON TARGET LABS's Recent FDA Approvals
New NDA/BLA approvals for ON TARGET LABS over the last two years — novel drugs only, excluding generics and label supplements.
ON TARGET LABS's Therapeutic Areas
ON TARGET LABS's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ON TARGET LABS's Top Competitors
ON TARGET LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ON TARGET LABS Pipeline Snapshot
Active clinical trials for ON TARGET LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CYTALUX leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/2 completed
- • Speed: 19 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2021-11-29
- Latest
- 2022-12-16
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges